Central venous catheter statistics at a glance
Central venous catheter data is useful because it sits at the intersection of market growth, hospital demand, and complication risk. The numbers below show both sides of the story: a market that is expanding and a clinical environment where placement choice and infection control still matter.
Fast facts
- The global central venous catheter market was valued at US$ 2.75 billion in 2024 (Market.us central venous catheter market report).
- The market is forecast to reach US$ 5.36 billion by 2034 (Market.us central venous catheter market report).
- The market is projected to grow at a 6.9% CAGR from 2025 to 2034 (Market.us central venous catheter market report).
- North America held more than 38.5% of the market in 2024 (Market.us central venous catheter market report).
- Hospitals accounted for 59.9% of end-user demand in 2024 (Market.us central venous catheter market report).
Contents
- Market size and growth
- Which segments matter most
- What the safety statistics show
- Access site and device choice
- Infection and thrombosis context
- How to read the data together
Market size and growth
The central venous catheter market is not a niche line item. It is a multi-billion-dollar category with a clear long-term growth profile.
The Market.us central venous catheter market report places the market at US$ 2.75 billion in 2024 and expects it to reach US$ 5.36 billion by 2034 (Market.us central venous catheter market report). That is a large enough spread to signal sustained demand rather than a short-term spike. The same report says the market is projected to grow at a 6.9% CAGR from 2025 to 2034 (Market.us central venous catheter market report).
A second benchmark from Grand View Research is close in magnitude and direction. Grand View Research values the global central venous catheters market at US$ 2,464.1 million in 2024 and forecasts US$ 3,542.2 million by 2030, with a 6.3% CAGR from 2024 to 2030 (Grand View Research catheter market statistics). The exact numbers differ because the reports are not identical in scope, but both point the same way: this is a steadily expanding market.
Why the growth matters
Growth in a device category like this usually reflects several overlapping forces:
- More complex inpatient care.
- Ongoing use in oncology, dialysis, and critical care.
- The need for reliable central access when peripheral access is not enough.
- Continuous replacement and procurement demand.
The market data tree also shows where these products sit in the broader supplies stack. Grand View Research places the category at the HC Supplies > Consumables > Catheter Market Outlook level (Grand View Research catheter market statistics), which is a reminder that central venous catheters are part of a wider high-turnover consumables ecosystem rather than a one-off capital purchase.
Which segments matter most
The segment mix gives a clearer picture of what buyers and providers actually use.
| Segment | 2024 share | Source label |
|---|---|---|
| North America | more than 38.5% | Market.us central venous catheter market report |
| Non-tunneled catheters | 39.8% | Market.us central venous catheter market report |
| Non-antimicrobial catheters | 80.4% | Market.us central venous catheter market report |
| Multiple-lumen designs | 39.8% | Market.us central venous catheter market report |
| Polyurethane | 46.8% | Market.us central venous catheter market report |
| Hospitals | 59.9% | Market.us central venous catheter market report |
A few patterns stand out from that table.
First, hospital demand dominates. At 59.9% of end-user demand in 2024, hospitals are the main consumption center (Market.us central venous catheter market report). That fits the clinical reality of ICU use, perioperative care, medication delivery, and longer inpatient treatment plans.
Second, non-tunneled catheters hold the largest product share at 39.8% (Market.us central venous catheter market report). That suggests a substantial share of use remains tied to shorter-term or more acute care needs.
Third, non-antimicrobial catheters account for 80.4% of the market in 2024 (Market.us central venous catheter market report). That is a strikingly large share and implies that antimicrobial protection is still a specialized rather than universal choice.
Fourth, multiple-lumen devices represent 39.8% of the market, and polyurethane represents 46.8% (Market.us central venous catheter market report). Together, those figures point to a market that values versatility and material performance.
How to interpret the segment mix
These shares should not be read as clinical recommendations by themselves. They are market structure data. But they do tell you what kinds of products dominate purchasing and usage patterns:
- Acute care needs remain central.
- Broad compatibility matters more than niche specialization in most of the market.
- Hospitals are still the main operating environment.
- Product design choices continue to balance handling, durability, and infection concerns.
What the safety statistics show
The safety data is where the clinical meaning becomes harder to ignore. Central venous access is routine, but it is not risk-free.
A JAMA Internal Medicine meta-analysis reported several complication rates tied to central venous catheter placement and use (JAMA Internal Medicine meta-analysis):
- CVC placement failure: 20.4 per 1000 catheters placed.
- Arterial puncture: 16.2 per 1000 catheters placed.
- Arterial cannulation: 2.8 per 1000 catheters placed.
- Pneumothorax: 4.4 per 1000 catheters placed.
- Malfunction: 5.5 per 1000 catheter-days.
- Infection: 4.8 per 1000 catheter-days.
- DVT: 2.7 per 1000 catheter-days.
- At least one serious complication in 30.2 per 1000 patients with a CVC for 3 days.
That last figure is the kind of statistic that changes how you think about everyday device use. A catheter can be standard practice and still carry a measurable cumulative burden of adverse events.
Ultrasound makes a measurable difference
The same meta-analysis provides a strong signal about guidance technique. Ultrasound guidance reduced arterial puncture to 13.5 events per 1000 catheters versus 68.8 without ultrasound (JAMA Internal Medicine meta-analysis). It also reduced pneumothorax to 2.4 events per 1000 catheters versus 9.9 without ultrasound (JAMA Internal Medicine meta-analysis).
Those are large relative differences. Even without adding any outside context, the direction is clear: technique matters, and image guidance improves safety metrics in the reported data.
A compact reading of the risk profile
If you group the meta-analysis findings by type of problem, you get a practical snapshot:
- Technical insertion problems appear early, including placement failure and arterial puncture.
- Mechanical issues and infections accumulate over time.
- Thrombotic events remain part of the device lifecycle.
That makes central venous catheter data especially useful for quality improvement because it covers both insertion quality and line maintenance.
Access site and device choice
Not all central access choices behave the same way. One randomized trial in the statistics set compared femoral and subclavian access and found very different complication patterns (JAMA randomized controlled trial).
| Outcome | Femoral access | Subclavian access | Source label |
|---|---|---|---|
| Overall infectious complications | 19.8% | 4.5% | JAMA randomized controlled trial |
| Infectious complication incidence density | 20 per 1000 catheter-days | 3.7 per 1000 catheter-days | JAMA randomized controlled trial |
| Major infectious complications | 4.4% | 1.5% | JAMA randomized controlled trial |
| Major infection incidence density | 4.5 per 1000 catheter-days | 1.2 per 1000 catheter-days | JAMA randomized controlled trial |
| Overall thrombotic complications | 21.5% | 1.9% | JAMA randomized controlled trial |
| Complete vessel thrombosis | 6% | 0% | JAMA randomized controlled trial |
| Overall mechanical complications | 17.3% | 18.8% | JAMA randomized controlled trial |
| Major mechanical complications | 1.4% | 2.8% | JAMA randomized controlled trial |
This table is useful because it shows that the access site changes different complication types in different ways.
The main pattern
The most obvious difference in the trial is the infection and thrombosis profile. Femoral access carried much higher infectious and thrombotic complication rates in the reported trial data (JAMA randomized controlled trial). Mechanical complications, however, were closer together.
That pattern is important because it separates the idea of “more complications” from the more specific reality that different access routes change different risk categories.
Why that matters for interpretation
For central venous catheter statistics, the important question is often not whether a device has risks. It is which risks increase, which decrease, and under what conditions. A line choice that preserves mechanical feasibility may still be a poor choice if infection or thrombosis risk rises sharply.
The American College of Cardiology summary of the same trial reinforces the thrombotic pattern, reporting 7 major catheter-related thromboses in the femoral group and 0 in the subclavian group (American College of Cardiology trial summary). It also reports 6% versus 0% major catheter-related thrombosis under one trial framing (American College of Cardiology trial summary).
Infection and thrombosis context
The broader infection data helps put the trial results into a wider hospital context.
CDC HAI Reports and Data show that acute care hospitals saw year-over-year decreases from 2023 to 2024 in several infection categories (CDC HAI Reports and Data):
- CLABSI decreased 9%.
- C. difficile infection decreased 11%.
- CAUTI decreased 10%.
- MRSA bloodstream events decreased 7%.
- SSI following colon surgery decreased 4%.
- Ventilator-associated events decreased 2%.
CDC’s 2024 HAI Progress Report also includes five infection categories relevant to hospital surveillance: CLABSI, CAUTI, VAE, SSI, and MRSA bloodstream events (CDC Current HAI Progress Report). The report uses data reported to NHSN through June 1, 2025 (CDC Current HAI Progress Report), and CDC identifies NHSN as the nation’s most widely used HAI tracking system (CDC HAI Reports and Data).
Why those numbers belong in a central line article
Central venous catheter risk does not exist in isolation. The line sits inside a larger prevention system that tracks infection burden across devices, procedures, and hospital workflows.
So when you look at catheter statistics, the relevant question is not only how often a line fails or becomes infected. It is also how hospitals trend on surveillance metrics that capture bloodstream and procedure-related harm.
The data in the tracker supports that framing from another angle too:
- A claims-database analysis reported CRBSI incidence rates ranging from 0.46 to 30 per 1000 catheter-days (PMC claims analysis).
- The same analysis reported CRBSI rates of 4.3% to 26% of placed catheters (PMC claims analysis).
- It also reported catheter-related thrombosis rates of 0.6% to 33% of catheters and 0.06 to 21 episodes per 1000 catheter-days (PMC claims analysis).
Those are wide ranges, which suggests that setting, patient population, and care process all matter.
Comparing device types in infection studies
A systematic review of bloodstream infections provides another useful comparison (PubMed bloodstream infection review):
- PICCs in hospitalized patients had a 2.4% infection risk and 2.1 per 1000 catheter-days.
- Cuffed and tunneled catheters had 22.5% infection risk and 1.6 per 1000 device-days.
- Central venous ports had 3.6% infection risk and 0.1 per 1000 device-days.
These figures do not collapse into a single ranking without context because the denominator and device use case differ. But they do show that device class changes the observed risk profile.
How to read the data together
A clean way to understand the full set of central venous catheter statistics is to separate market behavior from clinical risk.
Market side
- The category is growing steadily.
- North America is the largest regional market in the supplied data, at more than 38.5% and US$ 1.06 billion in 2024 (Market.us central venous catheter market report).
- Hospitals dominate end-user demand at 59.9% (Market.us central venous catheter market report).
- Non-tunneled, multiple-lumen, polyurethane, and non-antimicrobial products all hold major shares (Market.us central venous catheter market report).
Clinical side
- Placement complications are measurable and non-trivial.
- Ultrasound guidance materially lowers arterial puncture and pneumothorax in the meta-analysis (JAMA Internal Medicine meta-analysis).
- Femoral access showed worse infection and thrombosis outcomes than subclavian access in the randomized trial data (JAMA randomized controlled trial).
- Infection surveillance in hospitals is showing improvement in several categories, including CLABSI and MRSA bloodstream events (CDC HAI Reports and Data).
The practical takeaway from the numbers
The statistics point to a category that is both commercially stable and clinically consequential. The market is large enough to support many product types, but the outcome data keeps the focus on technique, access route, and ongoing surveillance.
That combination is why central venous catheter statistics remain useful to read from both sides at once. The market tells you what is widely used. The clinical data tells you what still needs careful management.
Quick reference list
- Global market size in 2024: US$ 2.75 billion (Market.us central venous catheter market report).
- Forecast market size by 2034: US$ 5.36 billion (Market.us central venous catheter market report).
- 2024 North America share: more than 38.5% (Market.us central venous catheter market report).
- 2024 hospital demand share: 59.9% (Market.us central venous catheter market report).
- Ultrasound effect on arterial puncture: 13.5 vs 68.8 per 1000 catheters (JAMA Internal Medicine meta-analysis).
- Femoral versus subclavian infection result: 19.8% vs 4.5% overall infectious complications (JAMA randomized controlled trial).
- CDC acute care CLABSI change: down 9% from 2023 to 2024 (CDC HAI Reports and Data).